OncoMatch/Clinical Trials/NCT06890858
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Is NCT06890858 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fasudil Hydrochloride for ovarian cancer.
Treatment: Fasudil Hydrochloride — This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A/A genotype ovarian cancer for treatment evaluation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
After platinum based chemotherapy at Zhejiang Provincial People's Hospital
Lab requirements
Liver function
Patients with abnormal liver function [excluded]
Patients with abnormal liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06890858 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages